Results 151 to 160 of about 3,567,577 (243)

Role of H-FABP values in determining the etiologic factors of the cardiac injuries [PDF]

, 2017
Güleser Akpınar, Ali Duman, Bedia Gülen, Mücahit Kapçı, Ertuğrul Altınbilek, İbrahim Ikızcelı   +5 more
openalex   +1 more source

In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma

Molecular Oncology, EarlyView.
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser, Jan Niklas Schäfer, Shraga Nahum Goldberg, Philipp Maximilian Kazmierczak, Moritz Nikolaus Gröper, Philipp Franz Linden, Elif Öcal, Tanja Burkard, Stefanie Corradini, Najib Ben Khaled, Moritz Wildgruber, Max Seidensticker, Jens Ricke, Matthias Stechele, Marianna Alunni‐Fabbroni   +14 more
wiley   +1 more source

Fibrinogen and Complement Factor H Induce Parkinsonian and Cognitive Impairment-Like Features in Mice. [PDF]

Cell Mol Neurobiol
Naskar A, Sachin M, Sengupta S, Bhadrachalam P, Hegde S, Yadav R, Pal PK, Alladi PA.   +7 more
europepmc   +1 more source

Genetic Manipulation of the Relapsing Fever Spirochete Borrelia hermsii Permits Novel Investigation into the Role of Factor H Binding in Borrelial Virulence

, 2011
Lindy M. Fine
openalex   +2 more sources

Recognition of Malondialdehyde-modified Proteins by the C Terminus of Complement Factor H Is Mediated via the Polyanion Binding Site and Impaired by Mutations Found in Atypical Hemolytic Uremic Syndrome [PDF]

, 2013
Satu Hyvärinen, Kôji Uchida, Markku Varjosalo, Reija Jokela, T. Sakari Jokiranta   +4 more
openalex   +1 more source

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

Molecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu, Jianlei Zhao, Aaban Asfar Azmi, Avanti Gupte, Jenna Thibodeau, Shuang Liu, Jinli Yang, Guan Wang, Holly Edwards, Lisa A. Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Julie Boerner, Maik Hüttemann, Jay Yang, Yue Wang, Jeffrey W. Taub, Yubin Ge   +18 more
wiley   +1 more source

Factor H-related 2 levels dictate FHR dimer composition. [PDF]

Sci Rep
Veuskens BRJ, Brouwer MC, van Mierlo G, Geissler J, van Leeuwen K, Derlagen M, Keijzer NCH, Hoogenboezem M, Kuijpers TW, Pouw RB.   +9 more
europepmc   +1 more source

Discovery of 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a Novel and Potent Vascular Endothelial Growth Factor Receptor Inhibitor

, 2008
Philip A. Harris, Amogh Boloor, Mui Cheung, Rakesh Kumar, Renae M. Crosby, Ronda G. Davis‐Ward, Andrea H. Epperly, Kevin W. Hinkle, R. Hunter, Jennifer H. Johnson, Victoria B. Knick, Christopher P. Laudeman, Deirdre K. Luttrell, Robert A. Mook, Robert T. Nolte, Sharon K. Rudolph, Jerzy R. Szewczyk, Anne T. Truesdale, James M. Veal, Liping Wang, Jeffrey A. Stafford   +20 more
openalex   +1 more source

A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression

Molecular Oncology, EarlyView.
Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.
Nicharat Sriratanasak, Bodee Nutho, Worawat Wattanathana, Narumon Phaonakrop, Bunnatut Panasawatwong, Katharina Erlenbach‐Wuensch, Sittiruk Roytrakul, Regine Schneider‐Stock, Pithi Chanvorachote   +8 more
wiley   +1 more source

Serum Complement Factor H: A Marker for Progression and Outcome Prediction Towards Immunotherapy in Cutaneous Squamous Cell Carcinoma. [PDF]

Cancers (Basel)
Geidel G, Adam L, Bänsch S, Fekade N, Deitert B, Rünger A, Kött J, Zell T, Heidrich I, Smit DJ, Pantel K, Schneider SW, Gebhardt C.   +12 more
europepmc   +1 more source